The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Nigel Irwin

School of Biomedical Sciences Research Institute

SAAD Centre for Pharmacy and Diabetes

University of Ulster

Coleraine

UK

[email]@ulster.ac.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • School of Biomedical Sciences Research Institute, SAAD Centre for Pharmacy and Diabetes, University of Ulster, Coleraine, UK. 2012
  • SAAD Centre for Pharmacy and Diabetes, School of Biomedical Sciences, University of Ulster, Coleraine, UK. 2004 - 2012

References

  1. Evaluation of the long-term effects of gastric inhibitory polypeptide-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice. Irwin, N., Montgomery, I.A., Flatt, P.R. Br. J. Nutr. (2012) [Pubmed]
  2. Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes. Irwin, N., Frizelle, P., Montgomery, I.A., Moffett, R.C., O'Harte, F.P., Flatt, P.R. Diabetologia (2012) [Pubmed]
  3. Alterations of glucose-dependent insulinotropic polypeptide (GIP) during cold acclimation. Irwin, N., Francis, J.M., Flatt, P.R. Regul. Pept. (2011) [Pubmed]
  4. Acute and long-term effects of peroxisome proliferator-activated receptor-γ activation on the function and insulin secretory responsiveness of clonal beta-cells. Irwin, N., McKinney, J.M., Bailey, C.J., McClenaghan, N.H., Flatt, P.R. Horm. Metab. Res. (2011) [Pubmed]
  5. Effects of metformin on BRIN-BD11 beta-cell insulin secretory desensitization induced by prolonged exposure to sulphonylureas. Irwin, N., McKinney, J.M., Bailey, C.J., Flatt, P.R., McClenaghan, N.H. Diabetes. Obes. Metab (2010) [Pubmed]
  6. Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. Irwin, N., Flatt, P.R., Patterson, S., Green, B.D. Eur. J. Pharmacol. (2010) [Pubmed]
  7. Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? Irwin, N., Gault, V., Flatt, P.R. Expert. Opin. Investig. Drugs (2010) [Pubmed]
  8. Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice. Irwin, N., McClean, P.L., Hunter, K., Flatt, P.R. Diabetes. Obes. Metab (2009) [Pubmed]
  9. Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice. Irwin, N., Hunter, K., Frizzell, N., Flatt, P.R. Regul. Pept. (2009) [Pubmed]
  10. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Irwin, N., Flatt, P.R. Diabetologia (2009) [Pubmed]
  11. Therapeutic potential for GIP receptor agonists and antagonists. Irwin, N., Flatt, P.R. Best Pract. Res. Clin. Endocrinol. Metab. (2009) [Pubmed]
  12. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes. Irwin, N., McClean, P.L., Patterson, S., Hunter, K., Flatt, P.R. Biol. Chem. (2009) [Pubmed]
  13. Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice. Irwin, N., Hunter, K., Frizzell, N., Flatt, P.R. Eur. J. Pharmacol. (2008) [Pubmed]
  14. Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice. Irwin, N., Hunter, K., Flatt, P.R. Peptides (2008) [Pubmed]
  15. Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice. Irwin, N., Hunter, K., Flatt, P.R. Peptides (2007) [Pubmed]
  16. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice. Irwin, N., McClean, P.L., Flatt, P.R. J. Pept. Sci. (2007) [Pubmed]
  17. Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice. Irwin, N., McClean, P.L., Harriott, P., Flatt, P.R. Exp. Gerontol. (2007) [Pubmed]
  18. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide. Irwin, N., McClean, P.L., Cassidy, R.S., O'harte, F.P., Green, B.D., Gault, V.A., Harriott, P., Flatt, P.R. Diabetes Metab. Res. Rev. (2007) [Pubmed]
  19. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Irwin, N., McClean, P.L., O'Harte, F.P., Gault, V.A., Harriott, P., Flatt, P.R. Diabetologia (2007) [Pubmed]
  20. Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice. Irwin, N., Green, B.D., Gault, V.A., Cassidy, R.S., O'Harte, F.P., Harriott, P., Flatt, P.R. Peptides (2006) [Pubmed]
  21. Stable agonist of glucose-dependent insulinotropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice. Irwin, N., Green, B.D., Gault, V.A., Harriot, P., O'Harte, F.P., Flatt, P.R. Exp. Gerontol. (2006) [Pubmed]
  22. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16). Irwin, N., Green, B.D., Parker, J.C., Gault, V.A., O'Harte, F.P., Flatt, P.R. Regul. Pept. (2006) [Pubmed]
  23. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Irwin, N., Clarke, G.C., Green, B.D., Greer, B., Harriott, P., Gault, V.A., O'Harte, F.P., Flatt, P.R. Biochem. Pharmacol. (2006) [Pubmed]
  24. Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). Irwin, N., Gault, V.A., Green, B.D., Greer, B., Harriott, P., Bailey, C.J., Flatt, P.R., O'Harte, F.P. Biol. Chem. (2005) [Pubmed]
  25. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Irwin, N., Gault, V.A., Green, B.D., Greer, B., McCluskey, J.T., Harriott, P., O'Harte, F.P., Flatt, P.R. Biol. Chem. (2004) [Pubmed]
 
WikiGenes - Universities